首页> 外文期刊>Retina >Intravitreous tissue plasminogen activator injection and pneumatic displacement in the management of submacular hemorrhage complicating scleral buckling procedures.
【24h】

Intravitreous tissue plasminogen activator injection and pneumatic displacement in the management of submacular hemorrhage complicating scleral buckling procedures.

机译:玻璃体内组织纤溶酶原激活剂注射和气动置换治疗黄斑下出血使巩膜屈曲过程复杂化。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the efficacy of recombinant tissue plasminogen activator (rTPA) and sulfur hexafluoride (SF6) in displacing submacular hemorrhage in patients who had scleral buckling procedures complicated by the development of submacular hemorrhage. Final visual acuity and complications of the procedures were evaluated. METHODS: Sequential intravitreal injections of 50 microg rTPA in 0.1 mL and 0.4 cc SF6 were performed in eight patients who showed submacular hemorrhage 1 day after a scleral buckling procedure. The fundus was checked daily for 3 days after the injection of TPA and gas, and then was followed every week for 1 month and then every 2 months. Patients were observed for at least 6 months. Visual acuity and the status of complications were evaluated. RESULTS: Submacular hemorrhage was totally or partially displaced extramacularly in all patients on the day after rTPA and SF6 injection. Vitreous hemorrhage was present in all patients. The retina was attached in all patients and no recurrent retinal detachment was noted. Visual acuity was improved at 6 months after treatment in all seven of the patients with macula-off retinal detachments compared to the preoperative visual acuity. The last patient who had a macula-sparing retinal detachment had decreased vision (20/25) at 6 months compared to preoperatively. CONCLUSIONS: Recombinant tissue plasminogen activator and SF6 injection is an easy procedure that is less complicated than and as effective as internal drainage in patients with submacular hemorrhage developing as a complication of scleral buckling procedures.
机译:目的:评估重组组织纤溶酶原激活物(rTPA)和六氟化硫(SF6)在巩膜屈曲手术并发黄斑下出血的患者中治疗黄斑下出血的疗效。评估最终的视力和手术并发症。方法:在巩膜扣紧术后1天出现黄斑下出血的8例患者中,分别在0.1 mL和0.4 cc SF6中分别进行了50 microg rTPA的玻璃体内注射。注射TPA和气体后,每天检查眼底3天,然后每周检查1个月,然后每2个月检查一次。观察患者至少6个月。评估视力和并发症的状态。结果:在rTPA和SF6注射后的第二天,所有患者的黄斑下出血全部或部分移位。所有患者均存在玻璃体出血。所有患者均附有视网膜,未见复发性视网膜脱离。与术前视力相比,在治疗后6个月的所有7例黄斑脱落型视网膜脱离患者中,视力都得到了改善。与术前相比,最后一个有视网膜黄斑剥落的患者在6个月时视力下降(20/25)。结论:重组组织纤维蛋白溶酶原激活剂和SF6注射是一种简单的方法,对于因巩膜扣紧术引起的并发症而发展的黄斑下出血患者,其内部引流不如其有效,且效果不如后者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号